Publications by authors named "Mary Jo Fidler"

Claim this Profile
P
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC).
Shirish M Gadgeel, Misako Nagasaka, Karen Dziubek, Thomas Braun, Khaled Hassan, Mary Jo Fidler

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Mary Jo Fidler

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difficult Decisions in the Multidisciplinary Treatment of Resectable Non-small Cell Lung Cancer.
Wara Naeem, Arsalan A Khan, Oluwamuyiwa W Adebayo, Minha Ansari, Nicole Geissen, Mary Jo Fidler

Ann Surg Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.
Greg Durm, Hirva Mamdani, Sandra Althouse, Susan Perkins, Salma K Jabbour, Mary Jo Fidler

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer.
Louis Filipiak, Koosha Paydary, Mary Jo Fidler, Helen J Ross

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn, Mary Jo Fidler

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Mary Jo Fidler

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.
Philip Bonomi, Hita Moudgalya, Sandra L Gomez, Palmi Shah, Sanjib Basu, Mary Jo Fidler

J Cachexia Sarcopenia Muscle· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
Narjust Florez, Lauren Kiel, Kelly Meza, Zihan Wei, Emanuele Mazzola, Mary Jo Fidler

Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, Melina E Marmarelis, Carolyn J Presley, Mary Jo Fidler

Lung Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nationwide analysis of salvage surgery for laryngeal cancer in the elderly.
Richard A Raad, Katie Holland, Ethan M Ritz, Bobby A Tajudeen, Samer Al-Khudari, Mary Jo Fidler

Head Neck· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unusual vasovagal-type autonomic dysfunction secondary to immune checkpoint inhibitor therapy.
Kelsey Danley, Mary Jo Fidler, Aliyah Sadaf, Tochukwu M Okwuosa

BMJ Case Rep· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies.
Kevin King, Ryan Rauch, Soumyajit Roy, Oleg Menyok, Ken Tatebe, Mary Jo Fidler

Anticancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.
Julie E Bauman, Ricklie Julian, Nabil F Saba, Trisha M Wise-Draper, Douglas R Adkins, Mary Jo Fidler

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Imad Tarhoni, Connor J Wakefield, Revathi Kollipara, Mary Jo Fidler, Marta Batus

J Immunol Methods· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
Nicole K Yun, Sherin J Rouhani, Christine M Bestvina, Ethan M Ritz, Brendan A Gilmore, Mary Jo Fidler

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer.
Anish Raman, Neilayan Sen, Ethan Ritz, Mary Jo Fidler, Peter Revenaugh

Am J Otolaryngol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer.
Jenna H Newman, C Brent Chesson, Nora L Herzog, Praveen K Bommareddy, Salvatore M Aspromonte, Mary Jo Fidler

Proc Natl Acad Sci U S A· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.
Philip Bonomi, Mary Jo Fidler, Palmi Shah, Jeffrey Borgia

Cancers (Basel)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Fabrice Barlesi, Edward B Garon, Dong-Wan Kim, Enriqueta Felip, Ji-Youn Han, Mary Jo Fidler

J Thorac Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, Balazs Halmos, Philip Bonomi

J Thorac Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Mary Jo Fidler, Cristina L Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine

BMC Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy.
Mary Jo Fidler, Casey Frankenberger, Richard Seto, Gabriela C Lobato, Cristina L Fhied

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients.
Philip Bonomi, Marta Batus, Mary Jo Fidler, Jeffrey A Borgia

Ann Transl Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma.
David J Sher, Chad G Rusthoven, Saad A Khan, Mary Jo Fidler, Hong Zhu

Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis